Trial reportBMC complementary medicine and therapies2026
Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial.
Trial report in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVasomotor symptoms are common during menopause and can impair quality of life. Although hormone therapy is effective, concerns about risks and adverse effects contribute to limited utilization, highlighting the need for non-hormonal options. Curcuminoids have antioxidant and anti-inflammatory properties and may improve vasomotor symptoms.
methodsThis 12-week, randomized, double-blind, placebo-controlled pilot proof-of-concept trial evaluated the preliminary efficacy of curcuminoids (1000 mg/day) versus placebo in healthy postmenopausal women (41–65 years; n = 40). The prespecified primary endpoint was the between-group difference in change in weekly hot flash frequency from baseline to Week 12. Secondary outcomes included changes in Menopause Rating Scale II (MRS II) and Menopause-Specific Quality of Life (MENQOL) scores. Safety and tolerability were assessed throughout.
resultsAll participants completed the intervention with high adherence and no serious adverse events. At Week 12 (primary endpoint), the between-group difference in change in weekly hot flash frequency from baseline was − 7.35 episodes/week (95% CI − 10.29 to − 4.41; p < 0.001), favoring curcuminoids; results were concordant using the Hodges–Lehmann estimate (− 6.00; 95% CI − 10.00 to − 4.00; p < 0.001). A significant between-group difference was also observed at Week 6. No statistically significant between-group differences were observed at Week 12 for total MENQOL or total MRS II, although the MENQOL vasomotor domain improved at Week 6 and showed supportive evidence in baseline-adjusted sensitivity analysis at Week 12.
conclusionIn this pilot proof-of-concept randomized trial, curcuminoid supplementation significantly reduced weekly hot flash frequency compared with placebo and showed a preliminary signal toward improved vasomotor-related quality of life, particularly at Week 6, with good tolerability. These preliminary, hypothesis-generating findings require confirmation in larger, adequately powered randomized trials, ideally incorporating biomarker endpoints.
trial registrationThai Clinical Trials Registry (TCTR) TCTR20241210002 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.